Mesoblast Limited (ASX:MSB)
2.390
-0.080 (-3.24%)
At close: Feb 5, 2026
Mesoblast Revenue
In the fiscal year ending June 30, 2025, Mesoblast had annual revenue of $17.20M USD with 191.39% growth. Mesoblast had revenue of $2.04M in the half year ending June 30, 2023, a decrease of -3.73%.
Revenue
$17.20M
Revenue Growth
+124.55%
P/S Ratio
117.60
Revenue / Employee
$212.32K
Employees
81
Market Cap
3.08B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 17.20M | 11.30M | 191.39% |
| Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
| Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
| Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
| Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
| Jun 30, 2020 | 32.16M | 15.43M | 92.30% |
| Jun 30, 2019 | 16.72M | -619.00K | -3.57% |
| Jun 30, 2018 | 17.34M | 14.93M | 618.95% |
| Jun 30, 2017 | 2.41M | -40.14M | -94.33% |
| Jun 30, 2016 | 42.55M | 22.79M | 115.31% |
| Jun 30, 2015 | 19.76M | - | - |
| Jun 30, 2013 | - | - | - |
| Jun 30, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Telix Pharmaceuticals | 1.01B |
| Neuren Pharmaceuticals | 218.86M |
| Clinuvel Pharmaceuticals | 95.02M |
| PYC Therapeutics | 23.49M |
| Clarity Pharmaceuticals | 9.46M |
| Orthocell | 7.55M |
| Racura Oncology | 6.04M |
| Botanix Pharmaceuticals | 5.79M |
Mesoblast News
- 7 days ago - Ryoncil® Net Revenues Increase for the Quarter to US$30M - GlobeNewsWire
- 8 days ago - Mesoblast Says Most Children Survive After Early Use Of FDA-Approved Cell Therapy For Organ Transplant Related Complication - Benzinga
- 9 days ago - Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment - GlobeNewsWire
- 15 days ago - FDA Signals Support For Mesoblast's Cell Therapy For Chronic Back Pain - Benzinga
- 17 days ago - FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy - GlobeNewsWire
- 26 days ago - Mesoblast (MESO) Sees Revenue Surge and Secures $125M Loan - GuruFocus
- 26 days ago - Mesoblast Stock Rises On Strong Year‑Over‑Year Growth In Ryoncil Sales - Benzinga
- 27 days ago - Mesoblast Surges As Flagship Product Ryoncil Delivers Strong Quarterly Sales Growth - Nasdaq